Glyscend Therapeutics
PrivateLast Round
Series A
Jun 11, 2020
Total Funding Raised
$22.7M
Company Overview
Glyscend Therapeutics is a biopharmaceutical company developing oral, first-in-class gut-targeted polymer therapies for the treatment of type 2 diabetes and obesity.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Advanced Materials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Glyscend Therapeutics Comparables
Compare Glyscend Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AltrixBio Inc. | 91% | |
| Syntis Bio, Inc. | 86% | |
| Aphaia Pharma | 81% | |
Glyscend Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 11, 2020 | ||||
| Grant | Sep 15, 2017 | ||||
| Grant | May 25, 2017 | ||||
| Grant | Nov 14, 2016 | ||||
| Grant | Jul 1, 2015 |
Glyscend Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Thiel Foundation | Seed, Series A |
| TEDCO | Convertible Debt |
| Santé Ventures | Series A |
| Breakout Ventures | Seed, Series A |
| Santé Ventures | Series A |
| Johnson & Johnson Innovation - JJDC, Inc. | Grant |
| National Science Foundation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 11, 2020
$21M round led by Brandon Capital and Santé Ventures.
- Sep 15, 2017
$1.2M grant from the National Science Foundation
Glyscend Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Glyscend Therapeutics's valuation, stock price, and market status.